Earnings and Growth Analysis : Hepion Pharmaceuticals (NASDAQ:HEPA)

0
69

Earnings results for Hepion Pharmaceuticals (NASDAQ:HEPA)

Hepion Pharmaceuticals, Inc. is estimated to report earnings on 10/06/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.19. The reported EPS for the same quarter last year was $-0.58.

Hepion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, October 6th, 2021 based off prior year’s report dates.

Analyst Opinion on Hepion Pharmaceuticals (NASDAQ:HEPA)

like Hepion Pharmaceuticals stock less than the stock of other Medical companies. 64.71% of gave Hepion Pharmaceuticals an outperform vote while medical companies recieve an average of 67.42% outperform votes by .

According to analysts’ consensus price target of $8.00, Hepion Pharmaceuticals has a forecasted upside of 422.9% from its current price of $1.53. Hepion Pharmaceuticals has received no research coverage in the past 90 days.

Dividend Strength: Hepion Pharmaceuticals (NASDAQ:HEPA)

Hepion Pharmaceuticals does not currently pay a dividend. Hepion Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Hepion Pharmaceuticals (NASDAQ:HEPA)

In the past three months, Hepion Pharmaceuticals insiders have not sold or bought any company stock. Only 1.20% of the stock of Hepion Pharmaceuticals is held by insiders. Only 14.21% of the stock of Hepion Pharmaceuticals is held by institutions.

Earnings and Valuation of Hepion Pharmaceuticals (NASDAQ:HEPA

Earnings for Hepion Pharmaceuticals are expected to decrease in the coming year, from ($0.50) to ($0.56) per share. Hepion Pharmaceuticals has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

More latest stories: here